XML 36 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation (Tables)
3 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2015 is as follows:

 

     Number
of
shares
     Weighted
average
exercise
price
 

Options outstanding at June 30, 2015

     12.5       $ 23.49   

Options granted

     —         $ —     

Less:

     

Options exercised

     (1.4    $ 18.90   

Options canceled or expired

     —         $ —     
  

 

 

    

Options outstanding at September 30, 2015

     11.1       $ 24.09   
  

 

 

    

Options exercisable at September 30, 2015

     9.4       $ 23.66   

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2015 is as follows:

 

     Number
of
shares
     Weighted
average
grant date
fair value
 

RSUs outstanding at June 30, 2015

     1.0       $ 37.63   

RSUs granted

     0.7       $ 40.62   

Less:

     

RSUs vested

     (0.3    $ 39.03   

RSUs canceled

     —         $ —     
  

 

 

    

RSUs outstanding at September 30, 2015

     1.4       $ 38.85   
  

 

 

    

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

 

     Three months ended
September 30,
 
     2015      2014  

Cost of molecular diagnostic testing

   $ 0.2       $ 0.2   

Cost of pharmaceutical and clinical services

     0.1         0.1   

Research and development expense

     1.6         0.8   

Selling, general, and administrative expense

     6.8         5.8   
  

 

 

    

 

 

 

Total share-based compensation expense

   $ 8.7       $ 6.9